ELECTRONIC SUPPLEMENTARY MATERIAL

Title: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with esophageal adenocarcinoma: results from a phase 1 cohort

Authors:

Benjamin Tan[1], Adnan Khattak[2], Enriqueta Felip[3], Karen Kelly[4], Patricia Rich[5], Ding Wang[6], Christoph Helwig[7], Isabelle Dussault[8], Laureen S. Ojalvo[8], Nicolas Isambert[9]

[1]Washington University School of Medicine, St Louis, MO, USA; [2]Fiona Stanley Hospital, Perth, Australia; [3]Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain; [4]University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA; [5]Cancer Treatment Centers of America, Atlanta, GA, USA; [6]Henry Ford Cancer Institute, Detroit, MI, USA; [7]Merck KGaA, Darmstadt, Germany; [8]EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany, and [9]Poitiers University Hospital, Poitiers, France

Corresponding author:

Nicolas Isambert

nicolas.isambert@chu-poitiers.fr

Supplemental Table S1. Concordance between independent review committee– and investigator-assessed confirmed best overall responses

		Independent review committee, *n*					
		Complete response	Partial response	Stable disease	Progressive disease	Not evaluable	
Investigator, *n*	Complete response	0	0	0	0	0	**0**
	Partial response	0	3	0	1	0	**4**
	Stable disease	0	3	4	0	0	**7**
	Progressive disease	0	0	0	12	0	**12**
	Not Evaluable	0	0	0	2	5	**7**
		0	**6**	**4**	**15**	**5**	**Total, *n***
		Total, *n*					

Supplemental Table S2. AEs of special interest

Preferred term, *n* (%)	*N*=30	
	Any grade	Grade 3[a]
Any irAE	7 (23.3)[b]	2 (6.7)
Immune-related rash	5 (16.7)	1 (3.3)
Rash	2 (6.7)	0
Rash macular	2 (6.7)	0
Rash generalized	1 (3.3)	1 (3.3)
Pruritus	1 (3.3)	0
Immune-related pituitary dysfunction	1 (3.3)	1 (3.3)
Hypophysitis	1 (3.3)	1 (3.3)
Immune-related pneumonitis	1 (3.3)	0
Immune-related thyroid disorders	1 (3.3)	0
Hyperthyroidism	1 (3.3)	0
Hypothyroidism	1 (3.3)	0
Skin lesions[c]	2 (6.7)[d]	1 (3.3)
KA	2 (6.7)	0
Bowen's disease[e]	1 (3.3)	1 (3.3)
SCC of skin	1 (3.3)	1 (3.3)
Actinic keratosis	1 (3.3)	0
Hyperkeratosis	1 (3.3)	0

[a]No patients experienced a grade >3 event. [b]Three patients experienced multiple different irAEs. [c]Includes actinic keratosis, basal cell carcinoma, Bowen's disease, hyperkeratosis, KA, lip SCC, and SCC of skin NCI-CTCAE v4.03 preferred terms. [d]One patient experienced multiple different skin lesions. [e]Also known as SCC in situ. *AE* adverse event, *irAE* immune-related adverse event, *KA* keratoacanthoma, *SCC* squamous cell carcinoma, *TRAE* treatment-related adverse event.

Supplemental Figure S1. Investigator-assessed Kaplan–Meier curve for progression-free survival (PFS)



Supplemental Figure S2. Expression of *TGFB1*, *TGFB2*, and *TGFB3* across phase 1 studies of bintrafusp alfa



AC adenocarcinoma, *SCC* squamous cell carcinoma.